Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - sunitinibum - capsule rigide - sunitinibum 25 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium max. 0.41 mg, povidonum k 30, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - sunitinibum - capsule rigide - sunitinibum 50 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium max. 0.81 mg, povidonum k 30, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - gefitinibum - compresse rivestite con film - gefitinibum 250 mg, lactosum monohydricum 163.5 mg, cellulosum microcristallinum, carmellosum natricum conexum, povidonum k 29-32, natrii laurilsulfas, magnesii stearas, Überzug: hypromellosum, macrogolum 300, e 171, e 172 (rubrum), e 172 (flavum), pro compresso obducto corresp. natrium 2.02 mg. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - neratinibum - compresse rivestite con film - neratinibum 40 mg a neratinibi malea, excipiens pro compresso haze. - brustkrebs - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - sunitinibum - capsule rigide - sunitinibum 12.5 mg, mannitolum, povidonum k 25, carmellosum natricum conexum corresp. natrium max. 0.15 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - sunitinibum - capsule rigide - sunitinibum 25 mg, mannitolum, povidonum k 25, carmellosum natricum conexum corresp. natrium max. 0.15 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - sunitinibum - capsule rigide - sunitinibum 37.5 mg, mannitolum, povidonum k 25, carmellosum natricum conexum corresp. natrium max. 0.23 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - sunitinibum - capsule rigide - sunitinibum 50 mg, mannitolum, povidonum k 25, carmellosum natricum conexum corresp. natrium max. 0.31 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - farmaco - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - carcinoma, polmone non a piccole cellule - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Unione Europea - italiano - EMA (European Medicines Agency)

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.